The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism by Eissa, Nermin et al.
1SCIEnTIFIC REPORts |  (2018) 8:13077  | DOI:10.1038/s41598-018-31385-7
www.nature.com/scientificreports
The histamine H3R antagonist 
DL77 attenuates autistic behaviors 
in a prenatal valproic acid-induced 
mouse model of autism
Nermin Eissa1, Petrilla Jayaprakash1, Sheikh Azimullah1, Shreesh K. Ojha1, Mohammed  
Al-Houqani2, Fakhreya Y. Jalal1, Dorota Łażewska3, Katarzyna Kieć-Kononowicz3 & 
Bassem Sadek1
Autistic spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in 
social communication and restricted/repetitive behavior patterns or interests. Antagonists targeting 
histamine H3 receptor (H3R) are considered potential therapeutic agents for the therapeutic 
management of different brain disorders, e.g., cognitive impairments. Therefore, the effects of 
subchronic treatment with the potent and selective H3R antagonist DL77 (5, 10, or 15 mg/kg, i.p.) 
on sociability, social novelty, anxiety, and aggressive/repetitive behavior in male Tuck-Ordinary (TO) 
mice with ASD-like behaviors induced by prenatal exposure to valproic acid (VPA, 500 mg/kg, i.p.) 
were evaluated using the three-chamber test (TCT), marble burying test (MBT), nestlet shredding 
test (NST), and elevated plus maze (EPM) test. The results showed that VPA-exposed mice exhibited 
significantly lower sociability and social novelty preference compared to VPA-exposed mice that 
were pretreated with DL77 (10 or 15 mg/kg, i.p.). VPA-exposed mice presented a significantly higher 
percentage of buried marbles in MBT and shredded nestlet significantly more in NST compared to the 
control groups. However, VPA-exposed animals pretreated with DL77 (10 or 15 mg/kg, i.p.) buried a 
reduced percentage of marbles in MBT and presented a significantly lower percentage of shredding 
behavior in NST. On the other hand, pretreatment with DL77 (5, 10, or 15 mg/kg, i.p.) failed to restore 
the disturbed anxiety levels and hyperactivity observed in VPA-exposed animals in EPM, whereas 
the reference drug donepezil (DOZ, 1 mg/kg, i.p.) significantly palliated the anxiety and reduced the 
hyperactivity measures of VPA-exposed mice. Furthermore, pretreatment with DL77 (10 or 15 mg/kg, 
i.p.) modulated oxidative stress status by increasing GSH and decreasing MDA, and it attenuated the 
proinflammatory cytokines IL-1β, IL-6 and TNF-α exacerbated by lipopolysaccharide (LPS) challenge, 
in VPA-exposed mouse brain tissue. Taken together, these results provide evidence that modulation 
of brain histaminergic neurotransmission, such as by subchronic administration of the H3R antagonist 
DL77, may serve as an effective pharmacological therapeutic target to rescue ASD-like behaviors in 
VPA-exposed animals, although further investigations are necessary to corroborate and expand these 
initial data.
Autistic spectrum disorder (ASD) is a neurodevelopmental brain disorder characterized by two major core 
behavioral symptoms: impairment in social interaction and communication and restricted/repetitive behavior 
patterns or interests, observed often before the age of three years and lasting throughout life1,2. Evidence suggests 
that genetic and environmental factors increase the incidence of ASD in children1. ASD has become a high prior-
ity for scientists and has attracted the public’s attention because of the reported increase in its prevalence, which 
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varies across studies but it is estimated to be 1 in 160 children worldwide and appears to have occurred globally3. 
The heterogeneity of clinical and behavioral symptoms in autistic children is part of the difficulty in understand-
ing the pathophysiology of this disorder. Consequently, no specific treatment can be effective for all autistic chil-
dren. Notably, cognitive problems are the most frequently reported features by parents of children with ASD, with 
prevalence estimates of 44–83% for these features in this population, underscoring the importance of recognizing 
these conditions in children with ASD as well as the need for more systematic research as an initial step in devel-
oping treatment strategies4. Importantly, behaviors inherent to ASD, such as impairments in communication, 
stereotype, aggression and attention-deficit hyperactivity disorder (ADHAD), may be exacerbated by increased 
memory disturbances1,2,5. Therefore, a successful pharmacological intervention strategy will not only palliate the 
impact of these symptomatic behaviors but also treat conditions that affect the ability of children to compensate 
for their deficits. In the last two decades, there has been a growing interest in the study of histamine in the CNS 
and its influence on behavior in both physiological conditions and brain disorders5. The histaminergic system 
is involved in basic physiological functions, such as the sleep-wake cycle, energy and endocrine homeostasis, 
sensory and motor functions, cognition, and attention, which are all severely affected in neuropsychiatric disor-
ders6–9. Thus, the brain histaminergic system is an attractive pharmacological target for therapeutic purposes, and 
many efforts have been made to develop drugs that could act on different histamine receptors (H1R, H2R, H3R 
and H4R)9,10. However, there are few studies related to the use of histamine receptor antagonists to treat autistic 
behavior. In 1997, it was proposed that famotidine, an antagonist of histamine H2R, would be a potential treat-
ment for children with ASD11. Famotidine has improved sociability in a patient diagnosed with schizophrenia 
(SCH)12, a disorder that shares various symptoms and genetic factors with ASD13,14. Later, famotidine was tested 
in a group of children with ASD, and 44% of them presented evidence of behavioral improvement. Moreover, the 
histamine H1R antagonist niaprazine has ameliorated symptoms such as unstable attention, resistance to change 
and frustration in patients with ASD15. Furthermore, it has been suggested that ligands of histamine H3R are 
considered potential therapeutic agents for the treatment of Alzheimer’s disease (AD), SCH, and narcolepsy16–18. 
In an animal model of SCH, the use of an H3R antagonist ameliorates behavioral impairments19, including spatial 
working memory deficit, an abnormality also found in patients with ASD6. Antagonism of H3R can attenuate 
impaired social behavior in rodents exposed to phencyclidine, a finding that may also have implications for 
ASD9. Interestingly, the old-generation H3R antagonist ciproxifan attenuates at least some sociability deficits 
and stereotypies present in the animal model of autism induced by valproic acid (VPA)1. Notably, embryonic 
exposure to VPA causes several molecular and neurochemical changes in zebrafish, which continue into adult-
hood and accompany impaired sociability, demonstrating the possible association between brain histaminergic 
system and the outcomes related to neuropsychiatric disorders20. In the postmortem dorsolateral prefrontal cor-
tex of 13 human subjects with ASD, significant alterations in the expression of key histamine genes, including 
all HR subtypes H1-4Rs, have been observed, signifying the involvement of modulated histaminergic signaling 
in the brain of ASD subjects21. The H3Rs are important modulators of numerous central control mechanisms22. 
Therefore, blockade of inhibitory histamine H3 auto-receptors reinforces histaminergic neurotransmission, 
while antagonism of H3 hetero-receptors accelerates the corticolimbic liberation of acetylcholine, norepineph-
rine, glutamate, dopamine, serotonin and gamma-aminobutyric acid (GABA)7,9,12. Considering these findings, 
we evaluated the effects of the novel potent and selective H3R antagonist DL77, which has confirmed high in vitro 
antagonist affinity in the subnanomolar range (pKi = 8.08)23–25, high in-vivo H3R antagonist central potency 
(ED50 = 2.1 ± 0.2 mg/kg, per os)23–25, and an excellent selectivity profile (pKi (hH4R) = 4.31; pKi (hH1R) = 6.18; 
pKi (α2R) = 2.10)23–26 on the ASD-like behavioral deficits in mice. The non-imidazole H3R antagonist DL77 
was tested in the current experiments because it has shown promising anticonvulsant and procognitive effects 
in different memory models in rodents24,27. DL77 (3–30 mg/kg, i.p.) has also exhibited encouraging effects on 
alcohol intake and preference in adult C57BL/6 mice25. Comprehensive as well as objective sociability and social 
novelty preferences of autistic animals were assessed using the three-chamber test (TCT) paradigm to evaluate 
the behavioral outcomes triggered by subchronic systemic pretreatment with DL77, applying donepezil (DOZ) 
as a reference drug. Additionally, the effects of DL77 on repetitive and anxious behavior using the marble bur-
ying test (MBT), nestlet shredding test (NST), and elevated plus maze (EPM) test were investigated, since ste-
reotyped repetitive as well as anxiety problems are considered possible predictors of intensified symptoms of 
ASD. Moreover, the effects of subchronic administration of the H3R antagonist DL77 on the expression of sev-
eral oxidative stress markers and proinflammatory cytokines were assessed in the cerebellum tissues (histamine 
H1-4Rs are present in high density)28, since neuroinflammation and oxidative stress are also considered possible 
predictors of intensified ASD-like symptoms in mice prenatally exposed VPA29. Furthermore, the abrogative 
effects of the CNS-penetrant H3R agonist (R)-α-methylhistamine (RAMH), the centrally acting H1R antagonist 
pyrilamine (PYR), and the H2R antagonist zolantidine (ZOL) on the DL77-provided behavioral and biochemical 
enhancements were assessed to further explain whether brain histaminergic neurotransmission is involved in the 
effects provided by the H3R antagonist DL77.
Materials and Methods
Animals. Female Tuck-Ordinary (TO) mice (aged 8 weeks, weighing 30–35 g) (Harlan, UK) bred in the local 
central animal facility of the College of Medicine and Health Sciences, United Arab Emirates University30, were 
mated. Pregnancy was confirmed by the presence of a vaginal plug on embryonic day 0 (E0). They were housed 
in plastic cages under a standard light/dark cycle (12 h light cycle, lights on 6 a.m.) at constant temperature 
22 + 1 °C, with free access to tap water and a standard rodent chow diet. On E12.5, 17 pregnant females were 
intraperitoneally (i.p.) injected with 500 mg/kg VPA (Sigma-Aldrich, St. Louis, MO, USA) dissolved in isotonic 
0.9% sodium chloride solution, and another 5 pregnant females received an equal volume of saline, as previously 
described31,32. Two females died after injection of VPA, and only 12 delivered pups. Pups from VPA-exposed 
mothers (Group 1) and from mothers that received saline (Group 2) were used in the study. All offspring were 
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weaned, gender-grouped at 3 weeks of age and randomly divided into several cages (5–6 mice/cage). Male off-
spring only from VPA-exposed mothers (Group 1) and from mothers that received saline (Group 2) were further 
divided into 2 subgroups, and then the mice in each subgroup were intraperitoneally (i.p.) treated as shown in 
the schematic experimental design (Fig. 1). The experiments of the current study were carried out between 9:00 
am and 3:00 pm, and all procedures were approved by the Institutional Animal Ethics Committee of College of 
Medicine and Health Sciences/United Arab Emirates University (Approval No. ERA-2017-5603). All authors 
confirm that all methods were carried out in accordance with relevant guidelines and regulations. To reduce the 
number of animals used, the levels of oxidative stress and proinflammatory cytokines were studied in the same 
groups of animals that were subjected to behavioral tests.
Drugs. The H3R antagonist DL77 [1-(3-(4-tert-pentylphenoxy) propyl)piperidine] was designed and synthe-
sized in the Department of Technology and Biotechnology of Drugs Krakow, Poland, according to a previously 
described procedure23. Sodium valproate (VPA) (500 mg/kg, i.p.), donepezil hydrochloride (DOZ) (1 mg/kg, i.p.) 
(reference drug), the H3R agonist RAMH (10 mg/kg, i.p.), the brain-penetrant H1R antagonist PYR (10 mg/
kg, i.p.), the brain-penetrant H2R antagonist ZOL (10 mg/kg, i.p.), LPS (from E. coli serotype 0111:B4), and the 
assay kit for GSH were all purchased from Sigma-Aldrich (St. Louis, MO, USA). The lipid peroxidation assay kit 
for estimation of malondialdehyde (MDA) was obtained from North West Life Science (Vancouver, WA, USA). 
For estimation of the proinflammatory cytokines IL-1β, IL-6 and TNF-α mediated by lipopolysaccharide (LPS), 
commercially available ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). All the reagents 
used in the study were of analytical grade. All drugs were dissolved in isotonic saline solution and injected intra-
peritoneally (i.p.) at a volume of 10 ml/kg adjusted to body weight, and all doses are expressed in terms of the free 
base.
Treatments. Different doses of DL77 (5, 10, and 15 mg/kg), DOZ 1 mg/kg or vehicle (saline) were injected 
once daily for 21 days. All doses were selected based on the results of previous studies and are expressed in terms 
of the free bases25,33,34. The H3R antagonists DL77 and DOZ or saline was administered 30–45 minutes before 
each behavioral test, and a group of 5–7 animals was used for each behavioral test. Behavioral testing was per-
formed between 9:00 am and 3:00 pm in an order randomized by group and in the following sequence once the 
animals were 50 days old: three-chamber test (TCT), elevated plus maze (EPM) test, marble burying test (MBT) 
and nestlet shredding test (NST). The subchronic treatment started one week before the behavioral test and was 
continued for a total of 21 days as described above. Then, the animals were deeply anesthetized with pentobarbi-
tal (40 mg/kg, i.p., body weight), and cardiac perfusion was carried out using 0.01 M phosphate-buffered saline 
(PBS) at pH 7.4 to wash out the blood. The brains were quickly removed and placed on an ice plate, where the two 
hemispheres were separated. The cerebellum was excised from the brain and snap-frozen in liquid nitrogen for 
biochemical tests35. The animals were injected with LPS (25 µg/kg, i.p.) two hours before the sacrifice according to 
previously published protocols29. All observers who performed the behavioral and biochemical tests were blinded 
to the experimental groups.
Study Design. Pregnant TO mice were injected i.p. with either VPA (500 mg/kg, i.p.) (Group 1) or saline 
(Group 2) on embryonic day 12.5 (E12.5)36 and returned to their home cages. VPA was dissolved in isotonic 
0.9% NaCl solution (saline), and the volume of injection was 10 ml/kg. Five pregnant mice were exposed to saline 
and gave birth to an average of 20–30 male offspring. Another group of pregnant mice (n = 17) were exposed to 
Figure 1. Schematic diagram of drug treatments, behavioral studies, and biochemical assessments with VPA 
mice. Pregnant mice were injected with VPA (500 mg/kg, i.p.) at embryonic day 12.5 (E12.5). Treatments started 
from postnatal day (P44). Injections (once daily) continued for 21 days until P64. Behavioral studies were 
carried starting from P51. All mice were then sacrificed at P64 for biochemical analyses.
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VPA; of that group, 12 gave birth to an average of 48–56 male offspring. All offspring were weaned, sexed at three 
weeks of age, and then randomly divided into several cages (5–6 mice/cage). Each cage contained mice of both 
experimental groups (Group 1: prenatally VPA-exposed offspring; Group 2: prenatally saline-exposed offspring). 
Group 1 was subdivided into nine subgroups of 5–7 VPA-exposed mice as follows: group II: VPA-exposed mice 
injected with saline; group III: VPA-exposed mice injected with DL77 (5 mg/kg, i.p.); group IV: VPA-exposed 
mice injected with DL77 (10 mg/kg, i.p.); group V: VPA-exposed mice injected with DL77 (15 mg/kg, i.p.); group 
VI: VPA-exposed mice injected with DOZ (1 mg/kg, i.p.); group IX: DL77 (10 mg/kg, i.p.) was co-administered 
with RAMH (10 mg/kg, i.p.); group X: DL77 (10 mg/kg, i.p.) was co-administered with PYR (10 mg/kg, i.p.); 
group XI: DL77 (10 mg/kg, i.p.) was co-administered with ZOL (10 mg/kg, i.p.) (Figs 2A–D and 3A–D). Group 2 
was subdivided into three subgroups of 5–7 saline-exposed mice as follows: group I: saline-exposed mice injected 
with saline; group VII: saline-exposed mice injected with DL77 (10 mg/kg, i.p.), and group VIII: saline-exposed 
mice injected with DOZ (1 mg/kg, i.p.) (Figs 2A–D and 3A–D).
Behavioral tests. Three-chamber test (TCT). TCT assesses cognition in the form of general sociability and 
interest in social novelty in rodents, identifying rodents with deficits in sociability and/or social novelty. The 
three-chamber test of social interaction and social novelty recognition was performed as described previously37, 
but with a slight modification in the apparatus, with one center chamber (40 × 20 × 22 cm) and two side chambers 
(40 × 20 × 22 cm) separated by two sliding doors under a light intensity of ~120 lux. The test was composed of 
four 10-min sessions. In the first session, a test mouse was habituated to the center chamber with the two doors 
closed for 5 min. In the second session, the doors were opened and a test mouse was allowed to explore all three 
chambers for 5 min. Before starting the third session, a stranger mouse (same age and gender with no previous 
contact with the test mouse), referred to as a novel mouse (NM), was placed in a small plastic cage in the either 
left or right chamber, chosen randomly to avoid side preference, while the other cage was kept empty in the 
opposite chamber and was referred to as a novel object (NO). In the third session, the test mouse was allowed to 
explore all three chambers and cages for 10 min. The time spent in the chamber with NM and around the cage 
was compared with the time spent in the chamber with NO. Additionally, the time spent exploring the NM and 
Figure 2. Effects of DL77 and DOZ on sociability assessed in TCT paradigm. After 10 minutes of 
acclimatization, male subjects were allowed to explore all chambers for 10 min. The results obtained were (A) 
time spent in the chamber of the novel object (NO), the novel mouse (NM), or the central chamber (CC); (B) 
time spent exploring the novel object (NO) or novel mouse (NM); (C) abrogative effects of subchronic (21 days) 
systemic co-administration of RAMH (10 mg/kg, i.p. for IX), PYR (10 mg/kg, i.p. for X), or ZOL (10 mg/kg,  
i.p., for XI) on the DL77 (10 mg)-provided enhancement of sociability. Saline-exposed mice were injected with 
saline in group I, DL77 (10 mg/kg, i.p.) in group VII, or DOZ (1 mg/kg, i.p.) in group VIII (A,B). DL77 (at a 
dose of 5, 10, or 15 mg/kg in group III, IV, or V, respectively) or DOZ (1 mg/kg, i.p. in groups VI and VIII) was 
administered subchronically for 21 days. Figure shows mean ± SEM (n = 6–7). #P < 0.05 vs. time spent in the 
chamber of NO (A–C) or vs. SI of VPA-exposed mice (group II) (D). (D) Sociability index (SI). *P < 0.05 vs. 
time spent exploring NM of DL77(10 mg)-treated VPA-exposed mice (group IV) (C) or vs. SI of (saline)-treated 
saline-exposed mice (group I) (D). $P < 0.05 vs. DL77(10 mg)-treated VPA-exposed mice (group IV) (D).
www.nature.com/scientificreports/
5SCIEnTIFIC REPORts |  (2018) 8:13077  | DOI:10.1038/s41598-018-31385-7
NO (direct contact) was recorded. As previously described, the sociability index (SI) and social novelty preference 
index (SNI) were evaluated to allow the direct comparison of social behavior of the treated groups38. The score for 
SI and for SNI ranged from 0.02–0.5; as the score became more positive and closer to 1, the more social was the 
tested animal. The SI was calculated using the following equation: (Fig. 2D)
SI [Time exploring novel mouse 1 Time exploring novel object]
[Time exploring novel mouse 1 Time exploring novel object]
= −
÷ + .
A new stranger mouse was added to the empty cage 10 min after the end of the third session, after which 
the test mouse was allowed to explore the environment for 10 min, which made up the fourth session. The new 
stranger mouse was referred to as NM, while the stranger mouse from the previous session was referred to as the 
familiar mouse (FM). The same parameters, namely, time spent in the chamber and exploratory time, were meas-
ured as in the previous session to evaluate the preference of the test mouse to NM over FM in the cage. Similarly, 
SNI was calculated, and it ranged from 0.02–0.5, where a value closer to 1 indicated that an animal was more 
interested in social novelty. The SNI was calculated as follows: (Fig. 3D)
SNI [Time exploring novel mouse Time exploring familiar mouse]
[Time exploring novel mouse Time exploring familiar mouse]
= −
÷ + .
The reason for the first session is that it might increase mouse exploration of side chambers relative to 
the center chamber in sessions 3 and 4. Another objective of habituation in the center chamber before the 
whole-apparatus habituation was to make the center chamber a familiar “home base” of the test mouse39, as 
reported in the original papers36,40. In addition, the time of habituations could be flexible (5–30 min)39. Stranger 
mice (8–16 weeks old) were habituated to the plastic cage in the three-chamber apparatus for 30 minutes 
Figure 3. Effects of DL77 and DOZ on social novelty assessed in TCT paradigm. After 10 minutes of 
acclimatization, male subjects were allowed to explore all chambers for 10 min. The results obtained were (A) 
time spent in the chamber of the familiar mouse (FM), novel mouse (NM), or central chamber (CC); (B) time 
spent exploring the familiar mouse (FM) or novel mouse (NM); (C) effects of subchronic (21 days) systemic 
co-administration of RAMH (10 mg/kg, i.p. for IX), PYR (10 mg/kg, i.p. for X), or ZOL (10 mg/kg, i.p., for XI) 
on the DL77 (10 mg)-provided enhancement of social novelty. Saline-exposed mice were injected with saline in 
group I, DL77 (10 mg/kg, i.p.) in group VII, or DOZ (1 mg/kg, i.p.) in group VIII (A,B). DL77 (at a dose of 5, 10, 
or 15 mg/kg in group III, IV, or V, respectively) or DOZ (1 mg/kg, i.p. in groups VI and VIII) was administered 
subchronically for 21 days. Figure shows mean ± SEM (n = 5–7). #P < 0.05 vs. time spent in the chamber FM 
(A–C) or vs. SNI of VPA-exposed mice (group II) (D). (D) Social novelty index (SNI). *P < 0.05 vs. time spent 
exploring NM of DL77(10 mg)-treated VPA-exposed mice (group IV) (C) or vs. SNI of (saline)-treated saline-
exposed mice (group I) (D). $P < 0.05 vs. DL77(10 mg)-treated VPA-exposed mice (group IV) (D).
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24 h before the test, as described previously36. Time spent in the chamber and sniffing were measured using 
EthoVision® Software (Noldus, Netherlands).
Marble burying test (MBT). MBT behavior is an accurate reflection of repetitive digging behavior41. The test was 
performed as previously reported with slight modifications41–43. Briefly, cages (26 cm × 48 cm × 20 cm) were filled 
with fresh, unscented mouse bedding material to a depth of 5 cm, and the bedding surface was leveled by placing 
another cage of the same size onto the surface of the bedding. The mouse was individually added for habituation. 
After 10 min, this mouse was removed, and 20 glass marbles (15 mm diameter) were carefully overlaid equidis-
tantly in a 4 × 5 arrangement. Each mouse was returned to its designated test cage and allowed to explore for 
30 min. The number of marbles buried (>50% marble covered by the bedding) was recorded44,45.
Nestlet Shredding test (NST). NST is a powerful behavioral assay to assess repetitive and compulsive-like behavior. 
It was performed by placing one mouse into a cage (19 cm × 29 cm × 13 cm). Fresh, unscented mouse bedding 
material was added to each cage to a depth of 0.5 cm, and the bedding was packed by placing another cage of the 
same size onto the surface of the bedding. Commercially available cotton fiber (nestlets) (5 cm × 5 cm, 5 mm 
thick, ~2.5 g each) was weighed on an analytical balance. One nestlet was placed on top of the bedding in each test 
cage, and the filter-top cover was placed on the cage. No food and water were given during the test. The mouse 
was left undisturbed in the cage with the nestlet for 30 minutes. Then, the mouse was then removed and returned 
to its home cage after test completion. The remaining intact nestlet material was removed from the cage with for-
ceps and allow to dry overnight. The remaining un-shredded nestlet was weighed, and the weight difference was 
divided by the starting weight to calculate percentage of nestlet shredded. We discarded the remaining shredded 
nestlet material and bedding44.
Elevated Plus Maze (EPM) test. The EPM test was performed as previously described46–49. Briefly, a four-armed 
apparatus was elevated 40 cm above the ground. It consisted of two opposite open arms (40 cm × 6 cm) and two 
opposite closed arms of the same size with high, black-painted walls. The arms were connected by a central square 
(6 cm × 6 cm). An animal was placed in the center of the maze facing an open arm. The maze was lighted with a 
60 W bulb approximately one meter above the maze. The amounts of time spent with the head and forepaws on 
the open arms and closed arms of the maze as well as the number of entries into each arm were measured over 
5 minutes using EthoVision® Software (Noldus, Netherlands). The maze was thoroughly cleaned with a tissue 
dampened with 70% (volume/volume; v/v) alcohol to remove the odor after each mouse was tested. The total 
number of entries into the closed arms is usually used as an index of locomotor activity in the test46–49.
Biochemical assessments. Enzyme-linked Immunosorbent Assay (ELISA). ELISA was used to quan-
tify the proinflammatory cytokines, mainly interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis 
factor-alpha (TNF-α), in the cerebellum. Commercially available ELISA kits (DuoSet) for IL-1β, IL-6, and TNF-α 
were purchased from R&D Systems. The levels of IL-1β, IL-6, and TNF-α were estimated as recommended by 
the manufacturer’s instructions. After brain extraction, the required tissues (mentioned above) were dissected, 
quickly frozen separately, and stored at −70 °C. On the day of assay, the neural tissues were homogenized on ice 
in the extraction buffer recommended by the manufacturer, RIPA buffer (50 mM Tris HCl, pH 7.4, 140 mM NaCl, 
1 mM EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate) with protease and phosphatase inhibitors (product 
No. 1861281, Thermo Scientific, Waltham, Massachusetts, United States). The homogenates were sonicated and 
centrifuged for 30 min at 12,500 rpm at 4 °C to remove tissue debris, and the resulting supernatant was used for 
the proinflammatory cytokine assessment and oxidative stress analysis. For proinflammatory cytokine analysis, 
the protein concentrations were determined using the Pierce® BCA Protein Assay Reagent Kit (Thermo Fisher 
Scientific Inc., Rockford, IL, USA). Briefly, 96-well plates were coated with the diluted capture antibody (100 μL) 
overnight at room temperature. Each well was aspirated and washed with wash buffer (0.05% Tween 20 in PBS 
0.01 M pH 7.4). The plate was blocked by adding reagent diluent (1% bovine serum albumin in PBS [300 μL]) 
for 1 hour and washed with wash buffer. Samples or standards (100 μL) were added to the well and incubated 
for 2 hours, then washed with wash buffer. Each well received detection antibody (100 μL), was incubated for 
2 hours at room temperature, and was washed with wash buffer. The well then received working solution (1:200) 
of streptavidin horseradish peroxidase (100 μL) and was further incubated for 30–40 minutes and then washed 
with wash buffer. The wells received substrate solution (100 μL) and incubated for 20 minutes. Finally, stop solu-
tion (2N H2SO4 [50 μL]) was added and mixed by gentle plate tapping. Immediately, the optical density of each 
well was read at 450 nm using a microplate absorbance reader (Sunrise, TECAN). The results are expressed as pg/
mg protein35,50.
Oxidative stress marker estimations. Lipid peroxidation product: malondialdehyde (MDA): An MDA detection 
kit (North West Life Science, Vancouver, WA, USA) was used to determine the amount of lipid peroxidation fol-
lowing the manufacturer’s instructions. Briefly, samples or calibrators (250 μL) were incubated in the presence of 
acid reagent and thiobarbituric acid (250 μL). Each sample was vortexed vigorously. Then, the samples were incu-
bated for 60 minutes at 60 °C and centrifuged at 10,000 × g for 2–3 minutes. The reaction mixture was transferred 
to a cuvette and its spectra at 532 nm recorded. The results are expressed as μM MDA/mg protein.
Glutathione (GSH): For the estimation of GSH, a commercially available GSH kit was used following the 
manufacturer’s instructions. Briefly, the samples were first deproteinized with 5% 5-sulfosalicylic acid solution 
and centrifuged to remove the precipitated protein. Supernatant was used to measure GSH. Samples or standards 
(10 μL) were incubated for 5 minutes with 150 μL of working mixture (assay buffer + 5,5′-dithiobis(2-nitrobenzoic 
acid) + GSH reductase) in 96-well plates. Diluted NADPH solution (50 μL) was added to each well and mixed 
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properly. The absorbance of the samples was measured at 412 nm with the kinetics for 5 minutes by using the 
microplate reader. The results are expressed as μM GSH/mg protein.
Statistics. The data were analyzed for normality by assessing the sample distribution or skewness (−1.5 to 
+1.5 considered normally distributed) as well as homogeneity of variance using Levene’s test. After the results 
had passed the tests for normality, they were analyzed using one-way analysis of variance (ANOVA) followed by 
the post hoc Fisher’s least significant difference (LSD) test. For statistical comparisons, the software package SPSS 
25.0 (IBM Middle East, Dubai, UAE) was used. The results are expressed as the means and standard errors (SEM). 
The P values less than 0.05 were considered statistically significant.
Results
Effects of DL77 on sociability deficits in VPA-exposed mice. The effect of subchronic systemic injec-
tion of DL77 at three different doses (5, 10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) on ASD-like sociability 
deficits in the TCT task in VPA-exposed mice are shown in Fig. 2A. The results of statistical analyses revealed 
that subchronic treatment with DL77 (10 mg/kg, i.p.) and DOZ (1 mg/kg) prior to TCT significantly enhanced 
sociability by increasing time spent in the chamber of the novel mouse compared to the time spent in the 
chamber of the novel object, with [F(7,40) = 4.467; P < 0.001] (Fig. 2A). As observed in the post hoc analysis by 
Fisher’s LSD test, VPA-exposed mice spent similar times in the chamber with NO and NM, with [F(1,10) = 0.004; 
P < 0.953] compared to saline-exposed animals, which spent significantly more time with NM over NO, with 
[F(1,10) = 12.20; P < 0.05] (Fig. 2A). DL77 (10 mg/kg) significantly improved time spent in the chamber of NM 
over NO in VPA-exposed mice, with [F(1,12) = 13.375; P < 0.05], and the observed improvement of time spent 
in the chamber with NM provided by DL77 (10 mg/kg) was comparable to that shown with DOZ (1 mg/kg), 
with [F(1,11) = 0.060; p = 0.810] (Fig. 2A). However, subchronic treatment of VPA-exposed mice with DL77 (5 or 
15 mg/kg) failed to improve the time spent in the chamber of NM versus NO, with [F(1,10) = 0.00; p = 0.989] and 
[F(1,12) = 0.984; p = 0.341], respectively (Fig. 2A). Furthermore, neither saline + saline (group I) vs. saline + DL77 
(10 mg) (group VII) nor saline + saline (group I) vs. saline + DOZ (1 mg) (group VIII) showed significant dif-
ferences (p = 0.120 and p = 0.110, respectively) (Fig. 2A). In addition, a statistical analysis of observed results 
indicated that subchronic treatment with DL77 (10 or 15 mg/kg, i.p.) exhibited a significant sociability-enhancing 
effect measured as time spent exploring novel mouse [F(7,43) = 4.98; P < 0.001] (Fig. 2B). As seen in Fig. 2B and in 
the post hoc analysis by Fisher’s LSD test, VPA-exposed mice spent similar exploratory times with NO and NM, 
with [F(1,10) = 1.035; p = 0.333] compared to saline-exposed animals, which spent significantly more exploratory 
time with NM versus NO, with [F(1,10) = 8.695; P < 0.05] (Fig. 2B). DL77 (10 or 15 mg/kg) showed significant 
improvements on sociability expressed as exploratory time spent with NM versus NO (both P values < 0.05) 
(Fig. 2B). However, DL77 (5 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) failed to significantly improve exploratory time 
spent with NM versus NO (both P values > 0.05) (Fig. 2B). Interestingly, neither saline + saline (group I) vs. 
saline + DL77 (10 mg) (group VI) nor saline + saline (group I) vs. saline + DOZ (1 mg) (group VIII) showed 
significant differences (p = 0.816 and p = 0.558, respectively) (Fig. 2B). As observed in the post hoc analysis by 
Fisher’s LSD test, the DL77-provided improvement of exploratory time spent with NM was reversed following 
RAMH or ZOL, with [F(1,11) = 17.997; P < 0.05] or [F(1,10) = 5.344; P < 0.05], respectively (Fig. 2C). However, PYR 
failed to reverse this sociability improvement: it had no significant effect compared to VPA-exposed mice treated 
with DL77 (10 mg/kg, i.p.) [F(1,12) = 0.321; p = 0.581] (Fig. 2C). Moreover, no significant difference in the socia-
bility index (SI) was observed for saline-exposed mice (group I) or VPA-exposed mice pretreated with 10 mg/kg 
of DL77 (group IV), indicating that VPA-exposed mice exhibited enhanced sociability performance when pre-
treated with DL77 (10 mg/kg) (Fig. 2D). Additionally, the observed results for SI values showed that the DL77 
(10 mg)-provided enhancement in sociability performance was completely abrogated when co-administered with 
the CNS-penetrant H3R agonist RAMH (10 mg/gg, i.p.) or the CNS-penetrant H2R antagonist ZOL (10 mg/kg, 
i.p.) (P < 0.05 for the comparison of group IV with group IX or XI) (Fig. 2D). However, the CNS-penetrant H1R 
antagonist PYR (10 mg/kg, i.p.) failed to reverse the observed effects of DL77 (10 mg/kg) (Fig. 2D).
Effects of DL77 on social novelty preference in VPA-exposed mice. Figure 3 shows the effects 
of subchronic administration of three different doses of DL77 (5, 10, and 15 mg/kg, i.p.) and DOZ (1 mg/kg, 
i.p.) on the time spent in the chamber with the familiar mouse (FM) and the novel mouse (NM). The results of 
post hoc analysis by Fisher’s LSD test indicated that saline-exposed mice spent significantly more time in the 
chamber of NM versus NO, with [F(1,9) = 11.324; P < 0.05] (Fig. 3A). However, VPA-exposed mice spent similar 
times in the chamber of NM versus NO, with [F(1,9) = 0.496; p = 0.499]. DL77 (5, 10 or 15 mg/kg, i.p.) or DOZ 
(1 mg/kg, i.p.) failed to provide significant differences in time spent in the chamber of NM versus FM, with 
[F(1,10) = 0.150; p = 0.707], [F(1,12) = 0.037; p = 0.851], [F(1,10) = 0.629; p = 0.446], and [F(1,10) = 0.061; p = 0.809], 
respectively (Fig. 3A). Noticeably, neither DL77 nor DOZ caused differences in time spent in the chamber with 
the novel mouse compared to the familiar mouse in the saline-exposed group, with [F(1,12) = 5.784; P < 0.05] for 
saline + saline (group I) vs. saline + DL77 (10 mg) (group VII) and [F(1,12) = 9.135; P < 0.05] for saline + saline 
(group I) + vs. saline + DOZ (1 mg) (group VIII) (Fig. 3A). In contrast, subchronic systemic pretreatment with 
DL77 at each dose (5, 10, or 15 mg/kg, i.p.) prior to TCT exhibited a significant enhancing effect on social novelty 
measured as time spent exploring NM versus FM, with [F(7,40) = 4.67; P < 0.001] (Fig. 3B). As seen in Fig. 3B and 
in the post hoc analysis by Fisher’s LSD test, VPA-exposed mice spent similar times exploring NM and FM, with 
[F(1,10) = 0.807; p = 0.390]. VPA-exposed mice pretreated with DL77 (10 or 15 mg/kg, i.p.) showed significant 
improvement in exploratory time spent with NM versus FM, with [F(1,10) = 6.964; P < 0.05] or [F(1,10) = 6.472; 
P < 0.05], respectively (Fig. 3B). However, DL77 (5 mg/kg, i.p.) and DOZ (1 mg/kg, i.p.) failed to improve the 
social novelty of VPA-exposed mice, with [F(1,10) = 0.362; p = 0.561] and [F(1,10) = 2.01; p = 0.187], respectively 
(Fig. 3B). Furthermore, no significant difference between saline + saline (group I) and saline + DL77 (10 mg) 
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(group VII) in exploratory time for NM versus FM was found (p = 0.320) (Fig. 3B). As depicted in Fig. 3C and 
observed in the post hoc analysis by Fisher’s LSD test, the DL77-provided enhancement of social novelty assessed 
by exploratory time spent with NM versus FM was reversed by RAMH or ZOL, with [F(1,10) = 0.331; p = 0.578] 
or [F(1,10) = 0.001; p = 0.972], respectively. However, PYR failed to reverse this social novelty improvement pro-
vided with DL77 (10 mg/kg, i.p.) in treated VPA mice, since the exploratory time spent with NM versus FM 
remained significant following subchronic co-administration of PYR (10 mg/kg, i.p.) and DL77 (10 mg/kg, i.p.), 
with [F(1,10) = 8.959; P < 0.05] (Fig. 3C). Moreover, no significant difference in the social novelty index (SNI) 
was observed between saline-exposed mice (group I) and VPA-exposed mice pretreated with 10 mg/kg of DL77 
(group IV), indicating that VPA-exposed mice exhibited enhanced social novelty performance when pretreated 
with DL77 (10 mg/kg) (Fig. 3D). Additionally, the results for SNI values showed that the DL77 (10 mg)-provided 
enhancement in social novelty performance was completely counteracted when the centrally active H3R agonist 
RAMH (10 mg/kg, i.p.) or the CNS-penetrant H2R antagonist ZOL (10 mg/kg, i.p.) was co-administered (P < 0.05 
for the comparison of group IV with group IX or XI) (Fig. 3D). However, the CNS-penetrant H1R antagonist 
PYR (10 mg/kg, i.p.) failed to reverse the enhancement of DL77-provided social novelty performance (Fig. 3D).
Effects DL77 on stereotyped repetitive behavior of VPA-exposed mice in MBT. The effect of 
subchronic systemic injection of DL77 (5, 10, or 15 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) on the increase in repeti-
tive behavior of VPA-exposed mice in MBT is shown in Fig. 4A,B. The results of statistical analyses showed that 
subchronic treatment with either 10 or 15 mg/kg DL77 or 1 mg/kg DOZ prior to MBT significantly decreased the 
elevated percentage of marbles buried by VPA-exposed mice [F(10,64) = 5.128; P < 0.001] (Fig. 4A). As observed 
in the post hoc analysis by Fisher’s LSD, VPA-exposed mice buried significantly more marbles compared to the 
saline-exposed animals, with [F(1,11) = 9.302; P < 0.05]. However, VPA-exposed mice pretreated with DL77 at 
10 mg/kg or 15 mg/kg exhibited significantly decreased percentages of buried marbles compared to saline-treated 
VPA-exposed mice, with [F(1,11) = 23.887; P < 0.001] and [F(1,11) = 23.870; P < 0.001], respectively (Fig. 4A). In 
contrast, DL77 (5 mg/kg, i.p.) failed to significantly decrease the percentage of buried marbles in VPA-exposed 
mice, with [F(1,11) = 3.674; p = 0.082] (Fig. 4A). Notably, no significant difference in the DL77-provided effect on 
percentage of buried marbles was observed between DL77 10 mg/kg and 15 mg/kg, with p = 0.588. Importantly, 
subchronic systemic administration of DOZ (1 mg/kg, i.p.) significantly decreased the percentage of marbles buried 
by VPA-exposed mice, with [F(1,11) = 7.563; P < 0.05]. Furthermore, no significant difference in the percentage of 
buried marbles was observed in the comparison of saline + saline (group I) vs. saline + DOZ (1 mg) (group VIII) 
(p = 0.880) (Fig. 4A). However, there was a significant decrease in the percentage of buried marbles in saline-exposed 
mice subchronically treated with DL77 (10 mg/kg, i.p.) (group VII) vs. saline + saline (group I), with [F(1,12) = 16.178; 
P < 0.05] (Fig. 4A). In another experiment, the DL77 (10 mg)-provided decrease in the percentage of buried marbles 
was reversed by RAMH, with [F(1,11) = 1.499; p = 0.246] for the comparison of VPA-exposed mice vs. VPA-exposed 
mice + DL77 (10 mg) + RAMH(10 mg). However, PYR and ZOL failed to reverse this DL77 (10 mg)-provided 
decrease in the percentage of buried marbles, as they had no significant effect compared to VPA-exposed mice treated 
with DL77 (10 mg/kg, i.p.), with [F(1,11) = 135.98; P < 0.001] and [F(1,11) = 15.311; P < 0.05], respectively (Fig. 4B).
Figure 4. Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in VPA mice exposed to MBT. 
(A) Repetitive marble-burying behavior was measured after a 30-minute testing session. VPA-exposed mice (II) 
demonstrated elevated stereotyped, repetitive behaviors that were significantly increased compared to saline-
exposed mice (I). DL77 (at a dose of 5, 10, or 15 mg/kg in group III, IV, or V, respectively) or DOZ (1 mg/kg, 
i.p. in groups VI and VIII) was administered subchronically for 21 days. (B) Effects of sub-chronic (21 days) 
systemic co-administration of RAMH (10 mg/kg, i.p. for IX), PYR (10 mg/kg, i.p. for X), or ZOL (10 mg/kg, 
i.p., for XI) on the DL77 (10 mg)-provided attenuation of stereotyped repetitive behavior of VPA-exposed mice 
in MBT. Saline-exposed mice were injected with saline in group I, DL77 (10 mg/kg, i.p.) in group VII, or DOZ 
(1 mg/kg, i.p.) in group VIII (A). Figures show mean ± SEM (n = 7). *P < 0.05 vs. saline-exposed mice. #P < 0.05 
vs. VPA-exposed mice.
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Effects DL77 on stereotyped repetitive behavior of VPA-exposed mice in NST. In the current 
study, the effect of subchronic systemic injection of DL77 (5, 10, or 15 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) on the 
increase in the percentage of shredded nestlet was assessed in NST (Fig. 5A,B). As observed in the post hoc anal-
ysis by Fisher’s LSD test, VPA-exposed mice shredded significantly more nestlet compared to the saline-exposed 
mice, with [F(1,10) = 17.851; P < 0.05]. VPA-exposed mice treated with DL77 (10 mg/kg or 15 mg/kg) exhibited 
a significantly lower percentage of shredded nestlet compared to VPA-exposed mice treated with saline, with 
[F(1,11) = 7.717; P < 0.05] and [F(1,11) = 10.549; P < 0.05], respectively (Fig. 5A). However, DL77 (5 mg/kg) failed to 
modulate the percentage of shredded nestlet in VPA-exposed mice, with [F(1,11) = 0.714; p = 0.416]. Notably, no 
significant difference in the DL77-provided effect on percentage of shredded nestlet was observed between the 
two doses of 10 and 15 mg/kg, with p = 0.842. Moreover, subchronic systemic administration of DOZ (1 mg/kg, 
i.p.) significantly lowered the percentage of shredded nestlet in VPA-exposed mice, with [F(1,11) = 8.869; P < 0.05]. 
Furthermore, neither saline + saline (group I) vs. saline + DL77 (10 mg) (group VII) nor saline + saline (group I) 
vs. saline + DOZ (1 mg) (group VIII) showed significant differences in shredded nestlet (p = 0.467 and p = 0.401, 
respectively) (Fig. 5A). As depicted in Fig. 5B and observed in the post hoc analysis by Fisher’s LSD test, the 
DL77 (10 mg)-provided decrease in the percentage of shredded nestlet was reversed following RAMH, with 
[F(1,11) = 0.028; p = 0.871] compared with saline-treated VPA-exposed mice (Fig. 5B). However, PYR and ZOL 
failed to reverse this DL77-provided decrease in the percentage of shredded nestlet, as they had no significant 
effect compared to VPA-exposed mice treated with DL77 (10 mg/kg, i.p.), with [F(1,11) = 9.532; P < 0.05] and 
[F(1,11) = 6.291; P < 0.05], respectively (Fig. 5B).
Effects of DL77 on anxiety and locomotor activity of VPA-exposed mice in EPM. Figure 6 shows 
the observed effects of subchronic systemic injection of saline or the H3R antagonist DL77 (5, 10, or 15 mg/kg, 
i.p.) on the anxiety parameters of VPA-exposed mice tested in the EPM, namely, the percentage of time spent 
in open arms (Fig. 6A), the number of entries into open arms (Fig. 6B), and locomotor activity expressed as the 
number of entries into closed arms (Fig. 6C). Subsequent post hoc analyses showed that DL77 administered at 5, 
10, or 15 mg/kg i.p. did not alter the percentage of time spent exploring the open arms of the maze during a 5 min 
session compared to saline-treated VPA-exposed mice, with [F(1,9) = 0.301; p = 0.596], [F(1,9) = 0.178; p = 0.683], 
or [F(1,9) = 0.563; p = 0.472], respectively (Fig. 6A). However, VPA-exposed mice pretreated with DOZ (1 mg) 
spent a significantly lesser percentage of time exploring the open arms compared to saline-treated VPA-exposed 
mice, with [F(1,7) = 11.835; P < 0.05] (Fig. 6A). Further analyses of data describing the number of entries and per-
centage of time in the open arms of the maze yielded for DL77 (5, 10, and 15 mg/kg i.p.) and DOZ (1 mg/kg, i.p.) 
practically the same results, with [F(1,9) = 1.746; p = 0.219], [F(1,9) = 1.199; p = 0.302], [F(1,9) = 1.211; p = 0.299], 
and [F(1,7) = 7.217; P < 0.05], respectively (Fig. 6B). Interestingly, the number of closed arm entries following 
subchronic systemic injection of DL77 (5, 10, or 15 mg/kg) was not significantly different, with [F(1,10) = 0.990; 
p = 0.343], [F(1,10) = 0.292; p = 0.601], and [F(1,10) = 0.059; p = 0.813], receptively. However, DOZ (1 mg)-treated 
VPA-exposed mice (group VI) showed fewer closed arm entries compared to saline-treated VPA-exposed mice 
(group II), with [F(1,10) = 6.598; P < 0.05] (Fig. 6C).
Figure 5. Effects of DL77 and DOZ on elevated stereotyped repetitive behavior in VPA mice exposed to NST. 
(A) Repetitive nestlet-shredding behavior was measured after a 30-minute testing session. VPA-exposed mice 
(II) demonstrated elevated stereotyped repetitive behaviors that were significantly increased compared to saline-
exposed mice (I). DL77 (at a dose of 5, 10, or 15 mg/kg in group III, IV, or V, respectively) or DOZ (1 mg/kg, 
i.p. in groups VI and VIII) was administered sub-chronically for 21 days. (B) Effects of subchronic (21 days) 
systemic co-administration of RAMH (10 mg/kg, i.p. for IX), PYR (10 mg/kg, i.p. for X), or ZOL (10 mg/kg, i.p., 
for XI) on DL77 (10 mg)-provided attenuation of stereotyped repetitive behavior of VPA-exposed mice in NST. 
Saline-exposed mice were injected with saline in group I, DL77 (10 mg/kg, i.p.) in group VII, or DOZ (1 mg/kg, 
i.p.) in group VIII (A). Figures show mean ± SEM (n = 7). *P < 0.05 vs. saline-exposed mice. #P < 0.05 vs. VPA-
exposed mice.
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Effect of DL77 on oxidative stress levels in brain tissue of VPA-exposed mice. The ability of 
DL77 to reduce oxidative stress in VPA-exposed mice was evaluated. Two parameters were measured, the MDA 
and GHS levels in VPA-exposed mouse cerebellum, which responded in an exacerbated way to the inflamma-
tory stimulus LPS. The results in Fig. 7A,B show that MDA was significantly elevated (P < 0.001) and GHS was 
significantly decreased (P < 0.05) in the brain tissues of VPA-exposed mice compared to saline-exposed mice 
(Fig. 7A,B). However, brain tissues of VPA-exposed mice subchronically pretreated with DL77 (10 or 15 mg/kg, 
i.p.) or DOZ (1 mg/kg, i.p.) showed a significant reduction of MDA (from 214.88 ± 12.58 μM to 112.77 ± 19.56, 
102.24 ± 16.60, and 97.32 ± 16.55 μM for DL77 (10 and 15 mg/kg) and DOZ (1 mg/kg), respectively) (P < 0.05) 
(Fig. 7A). In addition, subchronic administration of DL77 (10 or 15 mg/kg) or DOZ (1 mg/kg) significantly 
increased GHS compared to the saline-treated VPA-exposed animals (Fig. 7B). Meanwhile, the VPA-exposed 
mice subchronically pretreated with 5 mg/kg did not show any significant difference from the saline-treated 
VPA-exposed group (Fig. 7A,B). Moreover, subchronic systemic co-administration of RAMH (10 mg/kg, i.p.) 
partially abrogated (P < 0.005) the protective effects of DL77 (10 mg/kg, i.p.) against the VPA-induced decreased 
Figure 6. Effects of DL77 and DOZ pretreatment on exploratory behavior in the EPM test. VPA-exposed 
mice (II) demonstrated elevated impulsive attitude and deficits in cognition behaviors that were significantly 
increased compared to saline-exposed mice (I). DL77 (5, 10, or 15 mg/kg, i.p. in group III, IV, or V, respectively) 
or DOZ (1 mg/kg, i.p., in group VI) was administered subchronically for 21 days. DOZ (1 mg/kg, i.p. in groups 
VI and VIII) attenuated the increased percentage of time spent on the open arms of the EPM (A) the increased 
number of entries into the open arms (B) and the increased number of entries into the closed arms (C) in 
VPA mice. However, pretreatment with the H3R antagonist DL77 (5, 10, or 15 mg/kg, i.p.) did not affect any 
of the three parameters (A–C). Saline-exposed mice were injected with saline in group I and DOZ (1 mg/kg, 
i.p.) in group VIII (A–C). Data are expressed as the mean ± SEM (n = 5–7). *P < 0.05 vs. saline-exposed mice. 
#P < 0.05 vs. VPA-exposed mice.
Figure 7. Effects of DL77 and DOZ pretreatment on levels of malondialdehyde (MDA) and glutathione (GSH) 
in the cerebellum. VPA-exposed mice (II) showed a significant increase in MDA (A) and significant decrease in 
GSH (B) compared to saline-exposed mice (I). DL77 (5, 10, or 15 mg/kg, i.p. in group III, IV, or V, respectively) 
or DOZ (1 mg/kg, i.p. in group VI) was administered subchronically for 21 days. DL77 (10 or 15 mg/kg, i.p. in 
group IV or V, respectively) or DOZ (1 mg/kg, i.p. in group VI) significantly decreased MDA and significantly 
increased GSH. RAMH (10 mg/kg, i.p., co-administered in group IX) abrogated the modulating DL77 (10 mg)-
provided effects on oxidative stress levels (A,B). Saline-exposed mice were injected with saline in group I (A,B). 
Data are expressed as the mean ± SEM (n = 5–7). *P < 0.05 vs. saline-exposed mice. #P < 0.05 vs. VPA-exposed 
mice. $P < 0.05 vs. DL77 (10 mg)-treated VPA-exposed mice.
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level of MDA (Fig. 7A), and it completely reversed the DL77 (10 mg)-provided increase in GHS in VPA-exposed 
mice (Fig. 7B).
Effects of DL77 pretreatment on levels of proinflammatory cytokines IL-1β, IL-6 and TNF-α in 
brain tissue of VPA-exposed mice. The effects of DL77 on the levels of proinflammatory cytokines IL-1β, 
IL-6 and TNF-α in brain tissue of VPA-exposed mice that were exacerbated with LPS challenge were also assessed 
(Fig. 8A–C). The induction of ASD-like behaviors by prenatally administered VPA significantly increased IL-1β 
(Fig. 8A), IL-6 (Fig. 8B), and TNF-α (Fig. 8C) compared to the saline-exposed mice (all P < 0.001), while 
subchronic systemic administration of DL77 (5, 10 or 15 mg/kg, i.p.) or DOZ (1 mg/kg) significantly (P < 0.001) 
attenuated the rise of these proinflammatory cytokines in VPA-exposed mice (Fig. 8A–C). Notably, subchronic 
systemic co-administration of RAMH (10 mg/kg, i.p.) partially abrogated (P < 0.005) the protective effects of 
DL77 (10 mg/kg, i.p.) against VPA-induced elevation of proinflammatory cytokines (Fig. 8A–C).
Discussion
Antagonists targeting H3Rs are considered promising alternative treatments for different brain disorders, such 
as SCH, AD and narcolepsy9,51. The current study investigated, for the first time, the effects of the H3R antagonist 
DL77 on a mouse model of ASD-like behaviors induced by prenatal exposure to VPA. DL77 was chosen for the 
current study because it belongs to the class of non-imidazole H3R antagonists with improved selectivity and 
safety profile compared to the imidazole-based H3R antagonists, e.g., ciproxifan, which have several limitations 
as clinical candidates due to the presence of an imidazole heterocycle, which is responsible for numerous possible 
pharmacokinetic drawbacks, such as CYP450 inhibition, off-target activity, or lack of subtype selectivity, espe-
cially over H4R51.
Subchronic systemic administration of DL77 demonstrated ameliorating effects on social interaction deficits 
and stereotypies in VPA-exposed mice. In the TCT paradigm, sociability or social novelty is the tendency to 
spend time exploring an unfamiliar animal, compared to time spent exploring an object or a familiar animal, 
respectively. Systemic subchronic pretreatment with DL77 normalized the impairment in sociability demon-
strated by VPA-exposed mice, since these animals, when pretreated with DL77, presented longer times spent in 
the chamber of the novel mouse (improved sociability, Fig. 2B,D) and increased time spent exploring the novel 
mouse (improved social novelty, Fig. 3B,D), to levels similar to the saline-exposed mice. Numerous previous 
studies have focused on the procognitive effects of several H3R antagonists on social memory24,52–57, a behavio-
ral feature that is also altered in ASD58, but this study is the first one to assess the effects on of a non-imidazole 
based H3R antagonist on sociability deficits as ASD-like behaviors in VPA-exposed mice. Importantly, the 
sociability- and social novelty-enhancing effect observed for DL77 was dose-dependent, since DL77 (5 mg/kg) 
failed to improve sociability (Fig. 2B,D) or social novelty preference (Fig. 3B,D), while a dose of 10 mg/kg or 
15 mg/kg provided significant enhancement in sociability as well as social novelty behavior. An optimum effect 
was observed when the H3R antagonist DL77 was applied at a dose of 10 mg/kg, and a dose of 15 mg/kg DL77 did 
not significantly improve upon the DL77 (10 mg)-provided sociability or social novelty enhancement (Figs 2B,D 
and 3B,D). Interestingly, the observations for the dose-dependent effects of DL77 are in line with those previously 
observed for numerous H3R antagonists in preclinical experiments in different rodents (Benetti and Izquierdo, 
2013; Benetti et al., 2013; Sadek et al., 2016c). In addition, the observed results in regard to dose dependency 
strongly support our previous procognitive effects observed for the H3R antagonist DL77 (2.5, 5, or 10 mg/kg, 
i.p.) on different memory stages, namely, acquisition, consolidation, and retrieval in rats (Sadek et al., 2016c). 
Notably, the observations of sociability- and social novelty-enhancing effects for DL77 are in agreement with 
earlier experimental results observed with the imidazole-based H3R antagonist ciproxifan in Swiss mice1. In that 
Figure 8. Effects of DL77 and DOZ pretreatment on levels of proinflammatory cytokines IL-1β, IL-6 and 
TNF-α in the cerebellum. VPA-exposed mice (II) showed significantly increased IL-1β (A) IL-6 (B) and TNF-α 
(C) compared to saline-exposed mice (I) exacerbated by LPS challenge. DL77 (5, 10, or 15 mg/kg, i.p. in group 
III, IV, or V, respectively) or DOZ (1 mg/kg, i.p. in group VI) was administered subchronically for 21 days. 
DL77 (5, 10, or 15 mg/kg, i.p. in group III, IV, or V, respectively) or DOZ (1 mg/kg, i.p. in group VI) significantly 
decreased IL-1β (A), IL-6 (B) and TNF-α (C). RAMH (10 mg/kg, i.p., co-administered in group IX) reversed 
the modulating DL77 (10 mg)-provided effects on proinflammatory cytokines (A–C). Saline-exposed mice were 
injected with saline in group I (A–C). Data are expressed as the mean ± SEM (n = 5–7). *P < 0.05 vs. saline-
exposed mice. #P < 0.05 vs. VPA-exposed mice. $P < 0.05 vs. DL77 (10 mg)-treated VPA-exposed mice.
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study, ciproxifan (3 mg/kg, i.p.) attenuated sociability deficits in the VPA-induced ASD-like behaviors (Diego 
Baronio et al.1).
Interestingly, the DL77 (10 mg)-provided enhancing effects on sociability and social novelty were completely 
reversed when mice were co-administered the CNS-penetrant H3R agonist RAMH or with the CNS-penetrant 
H2R antagonist ZOL, but not with the centrally acting H1R antagonist PYR (Figs 2C,D and 3C,D). The lat-
ter observations indicate that brain histaminergic neurotransmission appears to be involved in the capacity 
of the H3R antagonist DL77 to facilitate the release brain histamine in specific brain areas7,9,10,59. The current 
results further indicate that histaminergic pathways, through activation of H2Rs, fundamentally contribute to 
neuronal pathways important for alteration of sociability and social novelty processes in the TCT paradigm in 
VPA-exposed mice. Notably, the reference drug DOZ failed to improve the exploratory time spent with the novel 
mouse compared to the time spent with the novel object (Fig. 2B,D). Additionally, DOZ did not improve the 
social novelty preference of VPA-exposed mice following subchronic systemic treatment (Fig. 3B,D). However, 
subchronic systemic pretreatment with DOZ significantly enhanced the time spent in the chamber of the novel 
mouse, indicating that sociability measures of VPA-exposed mice were improved after subchronic systemic treat-
ment with DOZ (1 mg/kg) (Fig. 2A). These observations could be explained by the results of a previous study in 
which the integrity of the central histaminergic system was found to be a crucial requirement for the biochemical 
and behavioral effects elicited by two procognitive compounds, namely, the H3R antagonist ABT-239 and the ace-
tylcholine esterase inhibitor DOZ34. Consequently, further investigations are necessary to assess the functionality 
of the central histaminergic system in VPA-exposed mice to further explain the behavioral results observed for 
DOZ in sociability as well as social novelty tests.
Stereotypy and rigidity of behavior are considered core features of ASD60,61. Moreover, the involvement of 
the brain histaminergic neurotransmission in the pathophysiology of Tourette syndrome, a condition com-
monly comorbid among ASD patients and featured by stereotypies, has been proposed and has been associ-
ated with a premature termination codon (W317X) responsible for the L-histidine decarboxylase (HDC) gene, 
the rate-limiting enzyme in biosynthesis of brain histamine. Consequently, such a premature termination of 
codon (W317X) impairs brain histaminergic neurotransmission16,62–65. In the current study, VPA-exposed mice 
subchronically pretreated with DL77 (10 or 15 mg/kg, i.p.) or with the reference drug DOZ (1 mg/kg, i.p.) displayed 
comparable reductions in stereotyped repetitive behavior in MBT (Fig. 4A). Moreover, the DL77 (10 mg/kg)- 
provided effects in MBT were entirely abrogated when mice were administered the CNS penetrant H3R ago-
nist RAMH, but not with the CNS-penetrant H1R antagonist PYR or the H2R antagonists ZOL (Fig. 4B). The 
mechanism by which the repetitive behavior is improved is not clear, but it might be explained by the capability 
of DL77, as a potent H3R antagonist, to mediate the release of different neurotransmitters besides histamine, 
such as dopamine, serotonin and acetylcholine, in several specific brain areas7,9,12,59. Therefore, measuring the 
levels of different brain neurotransmitters, including histamine, in various brain areas of the VPA-exposed mice 
with ASD-like behaviors as well as when treated with DL77 would further help us understand which neural cir-
cuits could be involved in this observed behavioral improvement. Interestingly, the results observed for DL77 in 
MBT are in agreement with a previous study in which acute systemic administration of the non-imidazole H3R 
antagonist ST-1283 significantly decreased the number of buried marbles and significantly shortened the digging 
duration in adult male C57BL/6 mice, without altering locomotor activity tested in an open field42.
Similarly, DL77 (10 or 15 mg/kg) attenuated the percentage of shredded nestlet in VPA-exposed mice with 
ASD-like behaviors in NST, and this reducing effect of DL77 on stereotyped repetitive behavior in NST was 
reversed with co-administration of the H3R agonist RAMH, but not the H1R antagonist PYR or the H2R antag-
onist ZOL (Fig. 5A,B). The results observed for DL77 in NST explain the current observations in MBT because 
DL77 facilitates the release of numerous central neurotransmitters besides histamine that are involved in repeti-
tive as well as anxious behaviors in different rodents7,9,12,59.
Ligands modulating anxiety levels or locomotion may give rise to a false-positive effect in these behavioral 
tests42,66. Therefore, the numbers of entries into the closed arms and into open arms in the EPM test were used 
as indicators of locomotor activity and anxiety levels, respectively. The results showed that DL77 at a dose of 5, 
10 or 15 mg/kg mg/kg did not alter anxiety-like levels nor locomotor activity in VPA-exposed mice as meas-
ured by the percentage of time spent or the number of entries into open arms and closed arms, respectively 
(Fig. 6A–C). Thus, the improvements in sociability, social novelty, and repetitive behaviors observed for DL77 in 
TCT, MBT and NST, respectively, appear unlikely to be associated with a modulating effect in anxiety levels or 
an increase in locomotor activity of the tested mice. In contrast, the reference drug DOZ (1 mg/kg, i.p.) attenu-
ated the percentage of time spent and the number of entries into open arms, indicating its enhancing effects on 
cognitive functions of VPA-exposed mice to better recognize and evaluate anxiety, as reflected in the decreased 
number of entries into open arms following subchronic systemic pretreatment VPA-exposed mice with DOZ 
(Fig. 6A–C). Moreover, the failure of DL77 at all doses to improve this abnormal anxiety and hyperactivity seen 
in VPA-exposed mice may have been due to the imbalance of several neurotransmitters that are dysregulated in 
ASD patients, such as serotonin67,68, glutamate and GABA68–71.
Several hypotheses have been proposed about the dual role of brain histamine in neurological disorders, and 
evidence has shown its critical involvement in the modulation of microglia-mediated neuroinflammation72. To 
determine a possible function of DL77 in tissue defense, oxidative stress parameters MDA and GSH were assessed 
in the cerebellum (Fig. 7A,B). The existence of lipid peroxidation is considered a key pathogenic event in brain 
tissues, resulting from an unbalanced ratio of radical oxygen species generation and the capacity for endoge-
nous cellular antioxidant defense73. The results showed that VPA-exposed mice with ASD-like behaviors had a 
significant increase in MDA, with a concomitant decline in GSH in the cerebellum tissues. GSH is considered to 
fight against lipid peroxidation, and it could have been depleted in the oxidative stress74, as demonstrated in the 
observed results (Fig. 7A,B). The results of the current study are in accordance with recent findings that histamine 
may provide protective effects under an inflammatory context72. However, subchronic systemic pretreatment 
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with DL77 (10 or 15 mg/kg, i.p.) inhibited lipid peroxidation, as evidenced by the reduced MDA followed by res-
toration of GSH (Fig. 7A,B). Interestingly, the imidazole-based H3R antagonists, namely, ciproxifan and cloben-
propit, control the elevation of various oxidative stress markers, including MDA and GSH, in amphetamine- or 
dizocilpine-augmented oxidative stress in an experimental mice model of SCH, indicating that H3R antagonists 
possess antioxidant activity, which might serve the antioxidant needs of SCH and at the same time control the 
symptomatic features of SCH75,76. These results in an SCH experimental model strongly support the current 
observations regarding DL77 in VPA-exposed mice with ASD-like behaviors, since SCH and ASD are often 
comorbid and share several symptomatic features9,76.
The protective role of histamine has also been reported in neurological conditions featured by 
microglia-induced neuroinflammation and, consequently, the involvement of brain histamine in the patho-
physiology of multiple sclerosis and other neurological diseases of several animal models72,77. The current study 
demonstrated a significant LPS-induced exacerbated rise in the expression of proinflammatory cytokines (IL-1β, 
IL-6, and TNF-α) in VPA-exposed mice (Fig. 7A–C). However, subchronic systemic pretreatment with DL77 
(5, 10, or 15 mg/kg, i.p.) significantly decreased the elevated levels of these proinflammatory cytokines in 
VPA-exposed mice. Interestingly, the CNS-penetrant H3R agonist, when co-administered with DL77, com-
pletely reversed the protective effect of DL77 against the elevated oxidative stress and partially abrogated the 
DL77-provided protective effects on proinflammatory cytokines (Fig. 7A–C), indicating the involvement of cen-
tral histaminergic neurotransmission in mediating the neuroprotective action of DL77 in VPA-exposed mice with 
ASD-like behaviors under inflammatory environments.
Conclusion
In summary, subchronic systemic administration of the non-imidazole H3R antagonist DL77 palliated sociability 
deficits and stereotypies present in the animal model of ASD-like behaviors induced by prenatal VPA exposure, 
demonstrating the therapeutic potential of H3R antagonists in the treatment of ASD. Moreover, modulation of 
central histaminergic neurotransmission by the H3R antagonist DL77 in an inflammatory context may have 
attenuated proinflammatory cytokine release and oxidative stress levels. However, additional preclinical experi-
ments in other behavioral test models and with several rodent species are necessary to expand these initial data 
and to understand the translational potential of H3R antagonists in the therapy of ASD.
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